Xofluza Granules 2% – a new formulation for influenza treatment and prophylaxis launched – Shionogi

Shionogi & Co., Ltd.  announced the launch  of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%.

Until now, Xofluza has only been available in tablet form, but there has been a need for a formulation suitable for patients who have difficulty taking tablets, such as younger children.  The newly launched granule formulation is easier to take and allows for appropriate dosing based on age and body weight.

Furthermore, with its availability for pediatric patients weighing less than 10 kg, it is expected to serve as a new treatment option for pediatric influenza, contributing to the care of a broader range of patients.